

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/502

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, CHEM ABS Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MESTERS R M ET AL: "ANGIOGENESIS BEI HAEMATOLOGISCHEN NEOPLASIEN" ONKOLOGIE, KARGER, FREIBURG, DE, vol. 24, no. SUPPL 5, 2001, pages 75-80, XP001135111 ISSN: 0378-584X abstract	1-15
Y	WO 98 35958 A (NOVARTIS ERFINDE VERWALT GMBH ;CIBA GEIGY AG (CH); TRAXLER PETER (C) 20 August 1998 (1998-08-20) cited in the application claims 1-15; examples 1-85	1-15
-/-		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 February 2004

Date of mailing of the international search report

13/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kling, I

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WOOD J M: "INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AS A NOVEL APPROACH FOR CANCER THERAPY" MEDICINA, BUENOS AIRES, AR, vol. 60, no. SUPPL 2, 2000, pages 41-47, XP008002456 ISSN: 0025-7680 abstract</p>	1-15
Y	<p>WOOD J M ET AL: "PTK787/ZK 222584, A NOVEL AND POTENT INHIBITOR OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASES, IMPAIRS VASCULAR ENDOTHELIAL GROWTH FACTOR-INDUCED RESPONSES AND TUMOR GROWTH AFTER ORAL ADMINISTRATION" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 8, 15 April 2000 (2000-04-15), pages 2178-2189, XP000971163 ISSN: 0008-5472 page 2184, right-hand column, last paragraph -page 2187, right-hand column, last paragraph</p>	1-15
Y	<p>LIN B K ET AL: "THE VEGF RECEPTOR TYROSINE KINASE INHIBITOR PTK787 INHIBITS PROLIFERATION AND MIGRATION OF MULTIPLE MYELOMA CELLS, AND REDUCES PARACRINE-MEDIATED RESPONSES TO THE BONE MARROW MICROENVIRONMENT" BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 98, no. 11, PART 1, 16 November 2001 (2001-11-16), page 166A XP001135110 ISSN: 0006-4971 abstract</p>	1-15
Y	<p>TRAXLER P ET AL: "TYROSINE KINASE INHIBITORS: FROM RATIONAL DESIGN TO CLINICAL TRIALS" MEDICINAL RESEARCH REVIEWS, NEW YORK, NY, US, vol. 21, no. 6, November 2001 (2001-11), pages 499-512, XP009012042 ISSN: 0198-6325 page 505, paragraph 3. -page 507, paragraph 4</p>	1-15
Y	<p>WO 02 41882 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH); TRAXLER PETER (CH)) 30 May 2002 (2002-05-30) claims 1-19</p>	1-15

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	WO 03 035047 A (NOVARTIS PHARMA GMBH ;NOVARTIS AG (CH); CHEN YING-NAN PAN (US); LA) 1 May 2003 (2003-05-01) claims 1-28	1-15
P,Y	WO 03 022282 A (NOVARTIS PHARMA GMBH ;NOVARTIS AG (CH); WOOD JEANETTE MARJORIE (CH) 20 March 2003 (2003-03-20) claims 1-27	1-15
P,X	WO 03 059354 A (KLUENDER HAROLD C E ;DUMAS JACQUES (US); ADAMS PAUL E (US); BAYER) 24 July 2003 (2003-07-24) page 76, line 1 -page 79, line 22; claims 1-15; example 1; table 1	1-15
P,X	ROBOZ GAIL J ET AL: "Phase I Trial of PTK787/ZK 222584, an Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Acute Myeloid Leukemia and Myelodysplastic Syndrome." BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), page Abstract No. 1308 XP009025184 44th Annual Meeting of the American Society of Hematology; Philadelphia, PA, USA; December 06-10, 2002 ISSN: 0006-4971 abstract	1-15
A	ESCRIBANO L ET AL: "EXPRESSION OF THE C-KIT (CD117) MOLECULE IN NORMAL AND MALIGNANT HEMATOPOIESIS" LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 30, no. 5/6, 1998, pages 459-466, XP001135035 ISSN: 1042-8194 abstract	1-15

INTERNATIONAL SEARCH REPORT

International Application No.

P 03/11084

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9835958	A	20-08-1998	AU 731852 B2	05-04-2001
			AU 6621898 A	08-09-1998
			BR 9807685 A	21-03-2000
			CN 1251097 T	19-04-2000
			CZ 9902853 A3	17-11-1999
			WO 9835958 A1	20-08-1998
			EP 0970070 A1	12-01-2000
			HU 0001046 A2	28-04-2001
			ID 23698 A	11-05-2000
			JP 2001508800 T	03-07-2001
			NO 993888 A	11-10-1999
			NZ 337064 A	27-04-2001
			PL 335113 A1	10-04-2000
			RU 2207132 C2	27-06-2003
			SK 109699 A3	13-03-2000
			TR 9901953 T2	21-10-1999
			US 2003191129 A1	09-10-2003
			US 6258812 B1	10-07-2001
			US 2002091261 A1	11-07-2002
			ZA 9801155 A	13-08-1998
WO 0241882	A	30-05-2002	AU 2368402 A	03-06-2002
			CA 2427184 A1	30-05-2002
			WO 0241882 A2	30-05-2002
			EP 1339458 A2	03-09-2003
WO 03035047	A	01-05-2003	WO 03035047 A2	01-05-2003
WO 03022282	A	20-03-2003	WO 03022282 A1	20-03-2003
WO 03059354	A	24-07-2003	WO 03059354 A2	24-07-2003